Please login by entering the password on your Zoladex password card.
If you require access to this website and don't have a Zoladex password you have 2 choices:
Contact your healthcare professional who started you on Zoladex
Contact AZ Medical Information on 0800 783 0033 or 01582 836 836.
Zoladex (pronounced Zoh-lah-dex) is an injectable hormonal treatment for men with certain types of prostate cancer. Zoladex contains a medicine called goserelin acetate and belongs to a class of medicines known as LHRH analogues (luteinizing hormone releasing hormone analogues or LHRHas).
Prostate cancer is the most common type of cancer among men. Each year, approximately 40,460 men in the UK are diagnosed with prostate cancer.1
Prostate cancer was first identified more than 150 years ago in a paper published in the medical journal The Lancet. It was originally thought to be a rare disease, mainly due to shorter life expectancies and poorer ways of detecting the disease in the 19th century. Pioneering work by Charles Huggins and Clarence Hodges in the 1940s showed that testosterone was essential for the growth of prostate cancer cells.2 This discovery eventually led to the LHRHa treatments we see used to treat prostate cancer today.
Zoladex is made by AstraZeneca UK Limited, one of the world’s leading pharmaceutical companies. Along with extensive research and manufacturing facilities, the company also offers information and support, such as this website, for both patients and healthcare professionals.
Zoladex is formulated, manufactured and packed for distribution at AstraZeneca’s major European facility in Macclesfield, Cheshire. The site covers around 100 acres and employs over 2,000 people. The manufacturing and packing process for Zoladex requires a complex aseptic technique to ensure the sterility of the drug and to avoid any possibility of product contamination. The facility houses multidisciplinary teams of scientists and specialists involved in chemistry, analytics, chemical engineering and project management.
2326200 DOP: Jan 2013